LIXTE BIOTECHNOLOGY HOLDINGS (LIXT)       0.5602  +0.01 (+2.73%)

Company Profile

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. The company is headquartered in East Setauket, New York and currently employs 3 full-time employees. The company went IPO on 2007-09-21. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has the therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The firm has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series consists of structures, which is treated not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which are useful for the treatment of chronic hereditary diseases.

Company Info

LIXTE BIOTECHNOLOGY HOLDINGS

No. 2, 248 Route 25A

East Setauket NEW YORK 11733

P: 13102032902.0

CEO: John S. Kovach

Employees: 3

Website: http://www.lixte.com/